Additional file 8 of Candidate methylation sites associated with endocrine therapy resistance in ER+/HER2- breast cancer

Additional file 8. Survival analysis using risk score. Results of survival analysis of the multi-locus signature using the risk score corrected for selected clinical variables in ER+/HER2-, TAM and AI cohorts.

附加文件8：基于风险评分的生存分析。本部分呈现了在雌激素受体阳性/人表皮生长因子受体2阴性（ER+/HER2-）、他莫昔芬（TAM）及芳香化酶抑制剂（AI）队列中，采用经选定临床变量校正后的风险评分对多位点特征开展生存分析的结果。